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6 years (range, 2–24 years). The majority were Lucarelli class III
(56%), with 38% class II and 6% class I. Median cell dose was
4.4  108 nucleated cells/kg (range, 2.1–19.7). Acute GVHD was
seen in 79 patients (51.9%) at a median time of 22.8 days (range,
7–96) after bone marrow transplantation. Grade I GVHD was seen
in 24%; grade II-IV GVHD, in 76%; grade III–IV GVHD, in
29%. Skin was involved in 69 patients (87.3%); the gastrointestinal
(GI) tract, in 38 (48%); and the liver, in 26 (32.9%). Eight patients
(10.1%) expired due to either progressive GVHD or cytomegalo-
virus infection infection, whereas the mortality rate in patients with
grade IV GVHDwas 25%. Of the evaluable 115 patients, 28 (24%)
developed chronic GVHD, which was limited in 25 (89.2%) and
extensive in 3 (10.8%). The skin was involved in 50% of the
patients, the GI tract in 64.2%, and the liver in 21%, with pulmo-
nary GVHD in 1 patient. GVHD-related mortality was seen in 2
patients (7.1%). No risk factors, including patient age, donor age,
sex mismatch, Lucarelli class, conditioning regimen, cell dose,
bacterial infections, VOD, and doses of MTx given were identiﬁed.
Reduction in the MTx dose from 15 to 10 mg/m2 did not increase
the risk of acute GVHD. In patients with acute GVHD, female to
male donor sex mismatch and cyclosporine-alone prophylaxis were
associated with an increased risk of developing grade III or IV
GVHD. The only risk factor identiﬁed for chronic GVHD was
acute GVHD. At median follow-up of 50 months (range, 3–145
months), 73.4% of patients with GVHD and 72.6% of patients
without GVHD were alive. GVHD is a major problem in patients
undergoing allogeneic BMT for thalassemia, although it is not
associated with increased mortality or secondary graft rejection.
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One potential approach for the effective disengagement of graft-
versus-leukemia (GVL) effects from graft-versus-host disease
(GVHD) after bone marrow transplantation (BMT) is the use of
nonmyeloablative (NM) conditioning to induce mixed chimerism
as a platform for the delayed transfer of donor T cells. In preclin-
ical models, CD8 T cells derived from donor leucocyte infusions
(DLIs) can induce powerful responses against tumors of host ori-
gin, but the effect lacks durability such that a rechallenge with
tumor inevitability leads to tumor progression and death. This
deﬁcit is associated with the failure of functional CD8 effector/
memory T cells (TE/M) to survive long-term post-DLI. We rea-
soned that strategies that augment the survival of GVH TE/M
might enhance the durability of the GVL response and, in the
absence of tissue inﬂammation induced by conditioning, might not
induce GVHD. One potential strategy is costimulation through
the tumor necrosis family receptor, OX40, which is expressed on
activated T cells, is antiapoptotic, and enhances recruitment of
TE/M to the memory pool. To test the feasibility of this approach,
we ﬁrst established mixed hematopoietic chimeras (MCs) in
B6D2F1 recipients using an NM protocol (3 Gy TBI intraperito-
neal injections of anti-CD154 and anti-CD8 monoclonal antibody
(mAb) on day 0), followed by infusion of 2  107 C57BL/6 bone
marrow cells. Ten weeks later, after the mAb had cleared from the
circulation, MC received DLI followed 2–5 days later by intraperi-
toneal injection of agonistic OX40 or control mAb. Administration
of OX40 mAb was associated with more rapid and more consistent
conversion to full donor chimerism induction as compared with
control mAb. By administering DLI that included CD8 T cells
from 2C transgenic mice that bear T-cell receptors speciﬁc for
recipient class I major histocompatibility complex Ld, we observed
that OX40 costimulation was associated with marked increases in
the numbers of 2C CD8 T cells in spleen, blood, lymph node,
and bone marrow and increased intracellular expression of inter-
feron-. By day 60 post-DLI, antihost CTL activity was clearly
detectable in anti-OX40 recipients but not in controls. Impor-
tantly, the enhancement of the magnitude and durability of the
GVH reaction could be achieved without the induction of signif-
icant clinical or histological GVHD. We conclude that OX40
costimulation after delayed DLI to established MC represents a
potential means of enhancing the magnitude and duration of a
GVH reaction, and hence GVL, without the induction of signiﬁ-
cant GVHD.
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Donor leucocyte infusions (DLI) given to established mixed
chimeras (MCs) can eliminate normal and malignant hematopoi-
etic cells without causing graft-versus-host disease (GVHD). DLI
given immediately after lethal irradiation leads to severe GVHD.
We examined the expansion, differentiation, and in vivo trafﬁcking
of GVH-reactive T cells after delayed DLI and compared these
outcomes when identical DLI was administered early after lethal
irradiation (TBI). C57BL/6 (B6) CD45.2  BALB/c 3 BALB/c
MC were prepared by TBI of BALB/c recipients and reconstitu-
tion with T-cell depleted bone marrow (TCD BM) derived from
donor and recipient strains. Ten weeks later, 107 CD45.1 B6 and
5 106 2C transgenic splenocytes were transferred. CD8 T cells
from 2C transgenic mice bear TCR speciﬁc for recipient class I
MHC Ld and can be detected using a clonotypic marker. For
comparison, identical DLI together with TCD BM was adminis-
tered to freshly irradiated BALB/c or B6 CD45.2 syngeneic recip-
ients. After delayed DLI, expansion of donor CD4 cells (on peak
day 10) preceded expansion of CD8 cells (on peak day 13) in the
spleen, with less accumulation in the lymph nodes, BM, liver and
lung, and no accumulation in the gut. In contrast, the kinetics of
donor T-cell expansion were more rapid in freshly irradiated re-
cipients with T cell responses peaking on day 4–7. Major trafﬁck-
ing of donor T cells to the gut was observed. After delayed DLI,
the kinetics of 2C CD8 T cell expansion were similar to those of
the polyclonal CD8 T-cell population. 2C CD8 T cells ac-
quired a memory/activation phenotype (CD44hi, CD45RBlo,
CD62Llo, CD49d, CD27, 47high) to a similar extent as
those in TBI mice developing GVHD. In additional experiments,
we transferred 4  106 B6 GFP T cells to freshly irradiated B6
xDBA/2 (B6D2F1) or B63B6D2F1 established MC and imaged
trafﬁcking to skin in real time by 2-photon imaging of postcapillary
venules of recipient ear pinnae. By day 5, we observed marked
rolling, tethering/adhesion, and extravasation of GFP T-cells in
freshly irradiated recipients. In contrast, GFP T cells failed to
trafﬁc to the skin on day 5 or 12 after transfer to established MC
despite their presence within the peripheral blood. Thus, in con-
trast to the response in freshly irradiated mice that develop
GVHD, GVH reactions induced by delayed DLI are characterized
by similar clonal expansion but failure of GVH-reactive T cells to
trafﬁc to the skin or the gut.
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Donor-derived T cells are thought to be the primary effectors of
chronic graft-versus-host disease (cGVHD); however, additional
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